Piperazine and Pyrazine containing molecules and their diverse pharmacological activities

Mohammad Asif

Abstract


Efforts were made to synthesize different heterocyclic compounds and their derivatives and were found to posses promising pharmacological compounds. Although piperazine and pyrazine moiety is six membered heterocyclic compounds but is fascinated by scientists because of the diverse biological activities by not only piperazine and pyrazine but its various substituted derivatives as well and having diverse pharmacological activities such antitumor, anticonvulsant, antidepressant, analgesic, antimicrobial, anti‐tubercular and anti diabetic, antihistamine, antiinflamatory and other activities. Some compounds also use as flavoring agent in foods. This review is focused on the piperazine and pyrazine derivatives due to its wider applications. They may replace many existing heterocyclic based pharmaceutical compounds. Many drug that containing piperazine and pyrazine moiety while several compounds are in clinical trials.


Keywords


Heterocyclic, antitumor, antidepressant, antipsychotic, anticonvulsant, antimicrobial, anti‐tubercular and anti diabetic, biological activities

Full Text:

PDF

References


. Katritzky, A.R., 1992. Heterocyclic Chemistry: An Academic Subject of Immense Industrial Importance. Chemistry of Heterocylic Compounds, 28(3): 241-259.

. Fan, W.Q. and A.R. Katritzky, 1996. In Comprehensive Heterocyclic Chemistry II.Katritzky, A.R., C.W. Rees and C.W.V. Scriven, Eds., Oxford, Elsevier, 4: 1.

. Valverde, M.G. and T. Torroba, 2005. Sulfur-Nitrogen Heterocycles. Molecules, 10: 318-320.

. Ghannoum M. Candida: A causative organism of an emerging infection. J. Invest. Dermatol 2001; 6: 188-196.

. Meher CP, Rao AM, Omar M. Piperazine-pyrazine and their multiple biological activities. Asian J Pharm Sci & Res, 2013, 3(1), 43-60.

. Hale SL, Kloner RA. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. J Cardiovasc Pharmacol Ther, 2006; 11(4): 249-55.

. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J. Am. Coll. Cardiol., 2006; 48(5): 992–8.

. Kinney JL, Evans RL. Evaluation of amoxapine. Clin Pharm, 1982; 1(5): 417–24.

. Gastpar M, Gastpar G, Gilsdorf U. Befuraline, its safety and efficacy in depressed inpatients. Pharmacopsychiatry. 1985; 18(6):351-5.

. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med, 2006, 354(12): 1243–52.

. Schoeffter P, Hoyer D. Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. Br J Pharmacol, 1988; 95 (3): 975-985.

. Fanelli RJ, Schuurman T, Glaser T, Traber J. Ipsapirone: a novel anxiolytic and selective 5-HT1A receptor ligand. Prog Clin & Biol Res, 1990; 361: 461–464.

. Cusack B, Nelson A, Richelson E. Binding of Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds. Psychopharmacol, 1994; 114 (4): 559–565.

. Tekes K, Tothfalusi L, Malomvolgyi B, Herman F, Magyar K. Studies on the biochemical mode of action of EGYT-475, a new antidepressant. Polish J Pharmacol & Pharm, 1987; 39(2): 203-11.

. Hamik; Oksenberg, D; Fischette, C; Peroutka, SJ. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biological Psychiatry, 1990, 28 (2): 99–109.

. Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging, 1994; 4(4): 331–55.

. De Paulis T. Drug evaluation: Vilazodone-a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs: The Inves Drugs J, 2007; 10 (3): 193–201.

. Gleeson, S; Barrett, JE. 5-HT1A agonist effects on punished responding of squirrel monkeys. Pharmacol, Biochem & Behav, 1990; 37(2): 335-7.

. Dahl E, Offer-Ohlsen D, Lillevold PE, Sandvik L. Transdermal scopolamine, oral meclozine, and placebo in motion sickness. Clin Pharmacol & Ther, 1984; 36(1), 116-20.

. Nicholson, A.N., et al., Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med, 2002. 73(6): p. 570-4.

. Simons FE, Simons KJ, Frith EM. The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. The J Allergy & Clin Immunol, 1984; 73(1 Pt 1): 69–75.

. Anderson, Philip; Knoben, James E.; Troutman, William G. Handbook of clinical drug data. New York: McGraw-Hill. 2002, p. 807.

. Grant, JA; Riethuisen, JM; Moulaert, B; DeVos, C; Gamalero, C.; Descalzi, D.; Folli, C.; Passalacqua, G. et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol, 2002; 88(2): 190–197.

. Bodiou C, Bavoux F. Niaprazine and side effects in pediatrics. Cooperative evaluation of French centers of pharmacovigilance. Thérapie, 1988; 43 (4): 307–11.

. Davis's Drug Guide for Nurses, Eighth Edition. F.A. Davis Company, 2005.

. Rees L. Chlorpromazine and allied phenothiazine derivatives. British Med J, 1960; 2(5197): 522–5.

. Tang L, Shukla PK, Wang ZJ. Trifluoperazine, an orally available clinically used drug, disrupts opioid antinociceptive tolerance. Neurosci Lett, 2006; 397(1-2): 1-4.

. Benson AJ. Effect of diphenidol and prochlorperazine on semicircular canal function in man. Aerospace Med, 1969; 40(6): 589-95.

. Vela JM, Buschmann H, Holenz J, Párraga A, Torrens A. Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. 2007; p. 520.

. Smith RL, Barrett RJ, Sanders-Bush E. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor. J Pharmacol & Exp Therap, 1995; 275(2):1050-7.

. Gambacorti-Passerini C. Part I: Milestones in personalised medicine--imatinib. Lancet Oncol, 2008; 9 (600): 600.

. Missale C, Pasinetti G, Govoni S, Spano PF, Trabucchi M. Fipexide: a new drug for the regulation of dopaminergic system at the macromolecular level. Bollettino Chimico Farmaceutico, 1983; 122(2):79-85.

. Manoury PM, Dumas AP, Najer H, Branceni D, Prouteau M, Lefevre-Borg FM. Synthesis and analgesic activities of some (4-substituted phenyl-1-piperazinyl)alkyl 2-aminobenzoates and 2-aminonicotinates. J Med Chem, 1979; 22(5): 554-9.

. Vaatstra WJ, Deiman-Van Aalst WM, Eigeman L.Du 24565, a quipazine derivative, a potent selective serotonin uptake inhibitor. Eur J Pharmacol, 1981; 70(2): 195-202.

. King LA. Forensic Chemistry of Substance Misuse. A Guide to Drug Control. Royal Soc Chem, 2009, p 100–102.

. Bossong MG, Van Dijk JP, Niesink RJ. Methylone and mCPP, two new drugs of abuse?. Addiction Biol, 2005; 10(4): 321–3.

. Westphal F, Junge T, Girreser U, Stobbe S, Pérez SB. Structure elucidation of a new designer benzylpiperazine: 4-bromo-2,5-dimethoxybenzylpiperazine. Forensic Sci Inter, 2009; 187 (1-3): 87–96.

. Antia U, Lee HS, Kydd RR, Tingle MD, Russell BR. Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci. Int. 2009; 186(1-3): 63-7.

. Burton, Michael E. Shaw, Leslie M. Schentag, Jerome J.; Evans, William E. Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring. Lippincott Williams & Wilkins; Fourth Edition edition. pp. 815. 2005.

. Onrust SV, McClellan K. Perospirone. CNS Drugs, 2001; 15 (4): 329–37.

. Hagop S. Akiskal; Mauricio Tohen. Bipolar Psychopharmacotherapy: Caring for the Patient. John Wiley & Sons. 2011, p. 209.

. Susan M. Fors and Bertil K. Olofsson. Alkylpyrazines, volatiles formed in the Maillard reaction. I. Determination of odour detection thresholds and odour intensity functions by dynamic olfactometry. Chemical Senses, 1985; 10 (3): 287–296.

. Adams J, Kauffman M. Development of the Proteasome Inhibitor Velcade (Bortezomib). Cancer Invest, 2004; 22(2): 304–11.

. Chatwal G.R., Pharmaceutical organic chemistry. p-2.19.

. Tripathy K. D. Pharmacology, 6th edition.

. Czerny M, Grosch W. Potent Odorants of Raw Arabica Coffee. Their Changes during Roasting. J Agr & Food Chem, 2000; 48 (3): 868–872.

. Marais J, Hunter JJ, Haasbroek PD. Effect of microclimate, season and region on Sauvignon blanc grape composition and wine quality. South Afr J Enol & Viticul, 1999; 20, 19-30.

. Lowy, Martin T., Meltzer, Herbert Y. Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist. Biol Psychiatry, 1988; 23(8): 818–28.

. Bonanni G, Ciccariello M, Mancini P, Pace V, Sagliaschi G. Concomitant cecoappendicular and urinary tuberculosis. Description of two rare cases: physiopathological and diagnostic remarks. Riv Eur Sci Med Farmacol, 1993; 15(3-4): 171–4.

. Iida K, Itoh K, Kumagai Y, et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 2004; 64(18): 6424–31.

. Spaia S, Magoula I, Tsapas G, Vayonas G. Effect of pyrazinamide and probenecid on peritoneal urate transport kinetics during continuous ambulatory peritoneal dialysis. Perit Dial Int, 2000; 20 (1): 47–52.

. Revill, P., Serradell, N., Bolos, J., Rosa, E. Telaprevir. Drugs of the Future, 2007; 32(9): 788.

. Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis". Harm Reduct J, 2009; 6: 25.

. Rosenzweig-Lipson, Sharon. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res, 2006; 1073-1074: 240–251.

. Schechter LE, Lin Q, Smith DL, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacol, 2008; 33 (6): 1323–35.

. Trump DL, Payne H, Miller K, et al. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate, 2011; 71(12): 1264–75.




DOI: http://dx.doi.org/10.7439/ijasr.v1i1.1766

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Refbacks

  • There are currently no refbacks.


Copyright (c) 2015 International Journal of Advances in Scientific Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.